Issue navigation
Volume 19, Issue Supplement_1, January 2025
Abstracts of the 20th Congress of ECCO Berlin, Germany, February 19-22, 2025
Oral Presentations
Sustainability in IBD and beyond - Session 1: Sustainability in IBD Care
OP01 Systemic antibody responses predict the onset of Inflammatory Bowel Disease up to 10 years before diagnosis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i1–i3, https://doi.org/10.1093/ecco-jcc/jjae190.0001
OP02 Tasty & Healthy Flexible Diet Induces clinical and biological Remission in Children and Young Adults with Mild-Moderate Crohn's Disease similar to EEN: results from the "TASTI-MM" randomized, physician-blinded, controlled trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i4, https://doi.org/10.1093/ecco-jcc/jjae190.0002
OP03 Mapping the observable IBDverse: Using massive-scale single-cell RNA sequencing of gut and blood samples to nominate genes, cell types and pathways driving IBD susceptibility
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i5–i6, https://doi.org/10.1093/ecco-jcc/jjae190.0003
Sustainability in IBD and beyond - Session 2: Novelties in IBD Care
OP04 Multi-Omics Biomarkers for Predicting Therapeutic Efficacy in Inflammatory Bowel Disease: Advancing Towards Tailored Treatments
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i7–i8, https://doi.org/10.1093/ecco-jcc/jjae190.0004
OP05 Efficacy and safety of autologous hematopoietic stem cell transplantation in refractory Crohn’s disease: outcomes from the international stem cell transplant consortium
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i9–i10, https://doi.org/10.1093/ecco-jcc/jjae190.0005
OP06 HLA-DQA1*05:01 is associated with loss of response to infliximab, and HLA DQA1*05:05 with loss of response to adalimumab in the Oxford OASIS study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i11–i12, https://doi.org/10.1093/ecco-jcc/jjae190.0006
Sustainability in IBD and beyond - Session 3: Sustaining remission - a joint effort
OP07 Psychosocial factors are associated with risk of flare in IBD; results from the PREdiCCt study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i13–i15, https://doi.org/10.1093/ecco-jcc/jjae190.0007
OP08 Histology-derived cell-cell interaction networks, linked to transcriptome profiling, define path to resolution in UC
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i16, https://doi.org/10.1093/ecco-jcc/jjae190.0008
Sustainability in IBD and beyond - Session 4: Novel Monitoring Tools
OP09 Dose intensification of vedolizumab is not effective in inducing endoscopic response in Crohn’s disease patients with endoscopic primary non-response
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i17–i18, https://doi.org/10.1093/ecco-jcc/jjae190.0009
OP10 Efficacy and safety of subcutaneous guselkumab induction therapy in patients with Ulcerative Colitis: Results through week 12 from the phase 3 ASTRO study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i19–i20, https://doi.org/10.1093/ecco-jcc/jjae190.0010
OP11 Analysing the T cell receptor beta chain repertoire of 2,800 Inflammatory Bowel Disease patients identifies public T cell responses involved in the pathogenesis of Crohn’s Disease and Ulcerative Colitis and quantifies the impact of surgery and therapy on the immune repertoire of IBD patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i21–i23, https://doi.org/10.1093/ecco-jcc/jjae190.0011
Sustainability in IBD and beyond - Session 5: Sustainable technology and consequences: ESGE-ECCO collaborative session on endoscopy
OP12 Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn’s disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i24–i26, https://doi.org/10.1093/ecco-jcc/jjae190.0012
OP13 Higher neoplasia detection rate and lower number of targeted biopsies associated with virtual chromoendoscopy in IBD surveillance: a real-world, multicentre UK study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i27–i28, https://doi.org/10.1093/ecco-jcc/jjae190.0013
OP14 The United European Gastroenterology green paper—climate change and gastroenterology
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i29–i30, https://doi.org/10.1093/ecco-jcc/jjae190.0014
Sustainability in IBD and beyond - Session 6: Surgical Sustainability
OP15 ECCO Topical Review on Pouch Disorders
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i31, https://doi.org/10.1093/ecco-jcc/jjae190.0015
OP16 Postoperative endoscopic recurrence after ileocecal resection for Crohn’s disease with Kono-S or side-to-side functional end anastomosis:12-18 months follow-up results from a Multicenter Prospective Randomized Trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i32–i33, https://doi.org/10.1093/ecco-jcc/jjae190.0016
OP17 Defining radiological healing in perianal fistulising Crohn’s Disease: a global modified Delphi consensus
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i34–i35, https://doi.org/10.1093/ecco-jcc/jjae190.0017
Sustainability in IBD and beyond - Session 7: Nutritional News
OP18 Multi-analytical Approaches Reveal Robust Gut Microbial Biomarkers for Inflammatory Bowel Disease Diagnosis: A Large-scale Cohort Study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i36–i37, https://doi.org/10.1093/ecco-jcc/jjae190.0018
OP19 Pre- and Post-diagnostic Metabolomic Biomarker Profiling of Over 700,000 Individuals in Three National Biobanks Enables Prediction of Inflammatory Bowel Disease Onset and Complications
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i38–i40, https://doi.org/10.1093/ecco-jcc/jjae190.0019
Sustainability in IBD and beyond - Session 8: IBD Horizons
OP20 Expanding the genetic spectrum of inflammatory bowel disease through large-scale exome sequencing
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i41–i42, https://doi.org/10.1093/ecco-jcc/jjae190.0020
OP21 MIF-CD74 signaling promotes intestinal LTi-like ILC3s activation and gut fibrosis via upregulating pSTAT3
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i43, https://doi.org/10.1093/ecco-jcc/jjae190.0021
OP22 NR1D1 Deficiency Induces CD47 Upregulation Impairing Macrophage Efferocytosis and Exacerbating Intestinal Inflammation in Ulcerative Colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i44, https://doi.org/10.1093/ecco-jcc/jjae190.0022
OP23 Neutrophil Niches and Therapy Resistance in Ulcerative Colitis: Spatial Atlas Insights
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i45–i46, https://doi.org/10.1093/ecco-jcc/jjae190.0023
OP24 TL1A-activated T cells as upstream regulators of perianal fistulizing disease-associated changes in the rectum of Crohn's Disease patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i47–i49, https://doi.org/10.1093/ecco-jcc/jjae190.0024
OP25 Young Researcher Award: Lymphocytic colitis can be transcriptionally divided into channelopathic and inflammatory lymphocytic colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i50, https://doi.org/10.1093/ecco-jcc/jjae190.0025
Sustainability in IBD and beyond - Session 9: Basic Science: Novel genetic insights
OP26 Disentangling the role of HLA proteins in shaping the T-cell repertoire in Inflammatory Bowel Disease using CDR3-QTL analysis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i51–i52, https://doi.org/10.1093/ecco-jcc/jjae190.0026
OP27 Unlocking Inflammatory Bowel Disease subtypes: a deep dive into transcriptomics and Machine Learning
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i53–i55, https://doi.org/10.1093/ecco-jcc/jjae190.0027
OP28 Anti-integrin αvβ6 autoantibodies are detected in preclinical, incident and established colonic Crohn’s disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i56–i58, https://doi.org/10.1093/ecco-jcc/jjae190.0028
OP29 Young Researcher Award: Breaking New Ground in IBD Research: Organoid Models as the Vanguard for Personalized Therapies
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i59–i60, https://doi.org/10.1093/ecco-jcc/jjae190.0029
OP30 Dissecting the genetic basis of clinical phenotype heterogeneity within IBD in more than 63,000 IBD patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i61, https://doi.org/10.1093/ecco-jcc/jjae190.0030
Sustainability in IBD and beyond - Session 10: Hot topics in IBD
OP31 Phase 1b study of SOR102, a novel, orally delivered bispecific anti-TNF/anti-IL-23 domain antibody in patients with mild to severe ulcerative colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i62–i63, https://doi.org/10.1093/ecco-jcc/jjae190.0031
OP32 Identifying clusters of antibiotic use patterns after the first episode of pouchitis in a population-based cohort
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i64–i65, https://doi.org/10.1093/ecco-jcc/jjae190.0032
OP33 Efficacy and safety of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn’s disease: Results through Week 48 from the phase 3 GRAVITI study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i66–i67, https://doi.org/10.1093/ecco-jcc/jjae190.0033
OP34 Mirikizumab demonstrates rapid improvements in bowel urgency severity, bowel urgency frequency, and stool deferral time in patients with moderately-to-severely active Ulcerative Colitis: 12-week interim results from the phase 3b LUCENT-URGE trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i68, https://doi.org/10.1093/ecco-jcc/jjae190.0034
OP35 Low remission recapture after ustekinumab dose optimization in Crohn’s disease: results of the randomized placebo-controlled double-blind REScUE study.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i69–i70, https://doi.org/10.1093/ecco-jcc/jjae190.0035
OP36 Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe Ulcerative Colitis: results of a multicenter, randomized, placebo-controlled phase II study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i71–i72, https://doi.org/10.1093/ecco-jcc/jjae190.0036
Sustainability in IBD and beyond - Session 11: Emerging challenges
OP37 Delineating molecular and microbial signatures across disease severity in Inflammatory Bowel Disease in adult treatment naive patients through single-cell transcriptomic and microbiome profiling.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i73, https://doi.org/10.1093/ecco-jcc/jjae190.0037
OP38 Comparative efficacy of infliximab and vedolizumab after failure of a first anti-TNF in patients with ulcerative colitis: a double-blind randomized controlled trial (EFFICACI)
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i74, https://doi.org/10.1093/ecco-jcc/jjae190.0038
OP39 Treatment with RO7790121 induces and maintains histologic and histologic-endoscopic improvement and remission in moderately to severely active ulcerative colitis – Results from TUSCANY-2
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i75–i76, https://doi.org/10.1093/ecco-jcc/jjae190.0039
OP40 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active Crohn’s disease: results from a phase 2b, randomised, double-blind, placebo-controlled dose-ranging, basket trial (RELIEVE UCCD)
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i77–i78, https://doi.org/10.1093/ecco-jcc/jjae190.0039A
OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i79–i80, https://doi.org/10.1093/ecco-jcc/jjae190.0039B
DOP001 Endoscopic and histologic outcomes in patients with moderate-to-severe Ulcerative Colitis treated with infliximab: A post hoc analysis of the Phase 3 LIBERTY-UC study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i81–i83, https://doi.org/10.1093/ecco-jcc/jjae190.0040
DOP002 Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE)
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i84–i86, https://doi.org/10.1093/ecco-jcc/jjae190.0041
DOP003 Cromoendoscopy versus second generation Narrow band Imaging for dysplasia detection in IBD. A prospective randomized controlled trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i87–i88, https://doi.org/10.1093/ecco-jcc/jjae190.0042
DOP004 Proactive fecal calprotectin testing in ulcerative colitis: Initial results of the PROMOTE UC study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i89–i90, https://doi.org/10.1093/ecco-jcc/jjae190.0043
DOP005 Long-term efficacy and safety of mirikizumab treatment for Crohn’s Disease: Results from the VIVID-2 open-label extension study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i91–i93, https://doi.org/10.1093/ecco-jcc/jjae190.0044
DOP006 Long term maintenance treatment with vedolizumab in pediatric IBD: a three-year follow-up of the prospective multicenter VEDOKIDS study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i94–i95, https://doi.org/10.1093/ecco-jcc/jjae190.0045
DOP007 Change in Histological inflammation in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i96–i97, https://doi.org/10.1093/ecco-jcc/jjae190.0046
DOP008 High clinical and endoscopic remission rate with Vedolizumab in early CD patients: the 2nd interim analysis from a prospective multicenter interventional Study (EARLY CD)
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i98–i99, https://doi.org/10.1093/ecco-jcc/jjae190.0047
DOP009 Effectiveness and Safety of Advanced Combination Treatment (ACT) in patients with refractory inflammatory bowel disease or concomitant immune mediated disease or extra-intestinal manifestations: A Multi-Center Canadian Study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i100–i101, https://doi.org/10.1093/ecco-jcc/jjae190.0048
DOP Session 2: Clinical Trials II
DOP010 Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i102–i104, https://doi.org/10.1093/ecco-jcc/jjae190.0049
DOP011 Colectomy rates of newly diagnosed Finnish Ulcerative Colitis patients are decreasing
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i105, https://doi.org/10.1093/ecco-jcc/jjae190.0050
DOP012 Promising effects of IMU-856, an orally available epigenetic modulator of barrier regeneration - biomarker findings from a Phase 1 clinical study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i106, https://doi.org/10.1093/ecco-jcc/jjae190.0051
DOP013 Risk of immune mediated inflammatory diseases associated with anti-TNFs and ustekinumab in Crohn’s disease: a nationwide population-based cohort study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i107, https://doi.org/10.1093/ecco-jcc/jjae190.0052
DOP014 Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i108–i110, https://doi.org/10.1093/ecco-jcc/jjae190.0053
DOP015 Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s Program
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i111–i112, https://doi.org/10.1093/ecco-jcc/jjae190.0054
DOP016 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i113–i115, https://doi.org/10.1093/ecco-jcc/jjae190.0055
DOP017 Infliximab induction fails to reach targets in Perianal Fistulizing Crohn’s Disease: first results from the ATLANTIC study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i116–i118, https://doi.org/10.1093/ecco-jcc/jjae190.0056
DOP018 Etrasimod for the treatment of Ulcerative Colitis: Up to 4 years of safety data from the global clinical programme
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i119–i121, https://doi.org/10.1093/ecco-jcc/jjae190.0057
DOP Session 3: Microbiology and Virology in IBD
DOP019 Reduced Gut Microbial Amino Acid Auxotrophies and Enhanced Tryptophan Degradation in Inflammatory Bowel Disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i122–i123, https://doi.org/10.1093/ecco-jcc/jjae190.0058
DOP020 Baseline Microbiota and Differences in Donor-Recipient Richness as Determinants of Fecal Microbiota Transplantation Efficacy in Ulcerative Colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i124–i125, https://doi.org/10.1093/ecco-jcc/jjae190.0059
DOP021 Appendectomy regulates intestinal flora-bile acid axis inhibits macrophage lipid metabolism and improves Ulcerative Colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i126–i127, https://doi.org/10.1093/ecco-jcc/jjae190.0060
DOP022 Shared and Distinct Features of the Gut Microbiome in Immune-mediated Inflammatory Diseases: Initial Analysis from the INTEGRATE Cohort Study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i128–i129, https://doi.org/10.1093/ecco-jcc/jjae190.0061
DOP023 Bifidobacterium-candida warfare in the gut of patients with ulcerative colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i130–i131, https://doi.org/10.1093/ecco-jcc/jjae190.0062
DOP024 Transport of pks+ E. coli derived genotoxin colibactin from bacteria into host cell
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i132, https://doi.org/10.1093/ecco-jcc/jjae190.0063
DOP025 Subjects sharing bacterial amplicon sequence variants exhibit differences in their IgA and IgG coating of gut bacteria, with enrichment of IgG binding for bacteria typically found in the oral cavity
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i133–i135, https://doi.org/10.1093/ecco-jcc/jjae190.0064
DOP026 Porphyromonas gingivalis secreted htpG disrupts TLR4/ PAPSS2-mediated mucin sulfation and aggravates ulcerative colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i136, https://doi.org/10.1093/ecco-jcc/jjae190.0065
DOP027 Caudovirales may trigger molecular mimicry mechanisms in Crohn’s Disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i137, https://doi.org/10.1093/ecco-jcc/jjae190.0066
DOP Session 4: Novel targets in IBD
DOP028 The resolution of fecal calprotectin configurations and their biological functions in gut inflammation
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i138, https://doi.org/10.1093/ecco-jcc/jjae190.0067
DOP029 SPP1 in colitis-associated colon cancer
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i139–i140, https://doi.org/10.1093/ecco-jcc/jjae190.0068
DOP030 Mucosal deficiency of mitochondria-driven humoral immunity is linked to Crohn’s Disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i141–i142, https://doi.org/10.1093/ecco-jcc/jjae190.0069
DOP031 Anti-IL-7 receptor plus anti-IL12/23 combination induces complete histological normalization in chronic colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i143, https://doi.org/10.1093/ecco-jcc/jjae190.0070
DOP032 Extracellular vesicles from Bifidobacterium longum Subspecies infantis attenuate intestinal inflammation via macrophage polarization
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i144–i145, https://doi.org/10.1093/ecco-jcc/jjae190.0071
DOP033 Pre-Clinical Development of SL-325, a High Affinity DR3 Blocking Antibody, for Durable Blockade of the DR3/TL1A Axis in Inflammatory Bowel Disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i146, https://doi.org/10.1093/ecco-jcc/jjae190.0072
DOP034 Intestinal stem cell dysfunction is driven by loss of HMGCS2-mediated ketogenic response in Ulcerative colitis and represents a novel therapeutic target
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i147–i148, https://doi.org/10.1093/ecco-jcc/jjae190.0073
DOP035 Anti-inflammatory potential of novel tethered agonists of the adhesion G protein-coupled receptor F5
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i149, https://doi.org/10.1093/ecco-jcc/jjae190.0074
DOP Session 5: Epidemiology and Environment
DOP037 The V-Sync study: Validation of the synchronization of the ENEIDA and UR-CARE registry
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i151, https://doi.org/10.1093/ecco-jcc/jjae190.0076
DOP038 Impact of prenatal and breastfeeding exposure to biologic drugs on the first-year anthropometric development of infants born to mothers with inflammatory bowel disease from DUMBO registry of GETECCU
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i152–i154, https://doi.org/10.1093/ecco-jcc/jjae190.0077
DOP039 Dietary methyl group donor intake alleviates the susceptibility to inflammatory bowel disease influenced by environmental pollution in a prospective cohort study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i155–i157, https://doi.org/10.1093/ecco-jcc/jjae190.0078
DOP040 Plant-based diets mitigate incidence, disease course and comorbidity of inflammatory bowel disease: evidence across eight European countries
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i158–i160, https://doi.org/10.1093/ecco-jcc/jjae190.0079
DOP041 The association between fermentable dietary fibre intake and risk of developing Crohn’s Disease: Results from the GEM Project
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i161, https://doi.org/10.1093/ecco-jcc/jjae190.0080
DOP042 Bowel damage and its correlation with the disability index in patients with recently diagnosed Crohn´s disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i162–i163, https://doi.org/10.1093/ecco-jcc/jjae190.0081
DOP043 Clinical outcomes and predictive factors differ in acute severe ulcerative colitis for East Asian and Western patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i164–i165, https://doi.org/10.1093/ecco-jcc/jjae190.0082
DOP044 Active disease on intestinal ultrasound in pregnancy is associated with an increased risk of adverse obstetric and neonatal outcomes: an international multi-centre prospective cohort study.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i166–i167, https://doi.org/10.1093/ecco-jcc/jjae190.0083
DOP045 Novel AI-Driven Detection, Localisation and Quantification of Neutrophils for Prediction of Early Response to Therapy in a Phase 2 Ulcerative Colitis Clinical Trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i168–i169, https://doi.org/10.1093/ecco-jcc/jjae190.0084
DOP Session 6: Clinical Trials III
DOP046 Effectiveness and Safety of Mirikizumab after switching from Ustekinumab in patients with moderate to severe Crohn’s disease: results from a long-term extension study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i170–i172, https://doi.org/10.1093/ecco-jcc/jjae190.0085
DOP047 Effectiveness of second-and-third line biologics in perianal Crohn’s disease (pCD) – a multicenter propensity score-matched study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i173–i174, https://doi.org/10.1093/ecco-jcc/jjae190.0086
DOP048 Efficacy and safety of dose de-escalation from 50 mg to 25 mg QD of obefazimod maintenance treatment: Analysis of a subset of patients with moderately to severely active ulcerative colitis (UC) who have completed 2 years with 25mg QD
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i175–i176, https://doi.org/10.1093/ecco-jcc/jjae190.0087
DOP049 Vedolizumab is more effective at inducing histo-endoscopic healing in early Crohn’s Disease compared to late CD, with comparable healing rates regardless of disease location: data from the LOVE-CD trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i177–i179, https://doi.org/10.1093/ecco-jcc/jjae190.0088
DOP050 Target achievement after 48 weeks of vedolizumab treatment in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i180–i181, https://doi.org/10.1093/ecco-jcc/jjae190.0089
DOP051 Upadacitinib for induction of remission in pediatric Ulcerative Colitis: An international multicenter study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i182–i183, https://doi.org/10.1093/ecco-jcc/jjae190.0090
DOP052 Etrasimod as induction and maintenance therapy in Asian patients with moderately to severely active Ulcerative Colitis: Results from the maintenance period of a randomised, double-blind, placebo-controlled, multi-centre Phase 3 study (ES101002)
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i184–i186, https://doi.org/10.1093/ecco-jcc/jjae190.0091
DOP053 Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA)
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i187–i189, https://doi.org/10.1093/ecco-jcc/jjae190.0092
DOP054 Early Histologic Response and Remission are Associated With Objective Control of Inflammation After One Year of Treatment With Mirikizumab in Moderately-to-Severely Active Crohn’s Disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i190–i191, https://doi.org/10.1093/ecco-jcc/jjae190.0093
DOP Session 7: Clinical Trials IV
DOP055 Upadacitinib for induction of remission in pediatric Crohn’s disease: An international multicenter study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i192–i193, https://doi.org/10.1093/ecco-jcc/jjae190.0094
DOP056 TDM-Based Dose-Intensification of Infliximab is not Superior to Standard Dosing in Patients with Acute Severe Ulcerative Colitis: Results from the TITRATE Study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i194–i195, https://doi.org/10.1093/ecco-jcc/jjae190.0095
DOP057 Early serum and faecal cytokines predict clinical outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i196, https://doi.org/10.1093/ecco-jcc/jjae190.0096
DOP058 Efficacy and Safety of Vedolizumab Combined with Upadacitinib in Moderate-to-Severe Ulcerative Colitis: A Multicenter, Prospective, Randomized Controlled Trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i197–i199, https://doi.org/10.1093/ecco-jcc/jjae190.0097
DOP059 Lack of significance of treatment-emergent anti-drug antibodies on efficacy of mirikizumab in patients with moderately-to-severely active Crohn’s Disease: Results from the VIVID-1 study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i200–i201, https://doi.org/10.1093/ecco-jcc/jjae190.0098
DOP060 Early disease efficacy of guselkumab therapy in biologic-naïve patients with moderately to severely active Crohn’s disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i202–i203, https://doi.org/10.1093/ecco-jcc/jjae190.0099
DOP061 RO7790121 shows early and rapid symptomatic remission in the treatment of moderately to severely active ulcerative colitis – Findings from the phase IIb TUSCANY-2 trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i204–i205, https://doi.org/10.1093/ecco-jcc/jjae190.0100
DOP062 Quantitative histologic features of the inflammatory microenvironment using digital pathology prior to adalimumab treatment allows prediction of response in patients with Ulcerative Colitis.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i206, https://doi.org/10.1093/ecco-jcc/jjae190.0101
DOP063 Hospitalised severe ulcerative colitis patients treated with rescue infliximab risk treatment failure due to underexposure caused by high drug clearance
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i207, https://doi.org/10.1093/ecco-jcc/jjae190.0102
DOP Session 8: Translational IBD
DOP064 Evaluation of pharmacological interventions in human Precision-Cut Intestinal Slices: insights into tissue-resident immunity in Inflammatory Bowel Diseases
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i208, https://doi.org/10.1093/ecco-jcc/jjae190.0103
DOP065 SRB1: a Best-in-Class CCR9 depleting antibody that restores immune homeostasis in IBD patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i209, https://doi.org/10.1093/ecco-jcc/jjae190.0104
DOP066 Temperature-triggered in situ forming lipidic gel for local treatment of ulcerative colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i210, https://doi.org/10.1093/ecco-jcc/jjae190.0105
DOP067 Selective JAK1 blockade with Upadacitinib is effective in immune checkpoint inhibitor-induced colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i211, https://doi.org/10.1093/ecco-jcc/jjae190.0106
DOP068 Vedolizumab counteracts Parkinson’s disease-related brain pathology driven by gut-primed IBD T cells
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i212–i213, https://doi.org/10.1093/ecco-jcc/jjae190.0107
DOP069 Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i214–i215, https://doi.org/10.1093/ecco-jcc/jjae190.0108
DOP070 Activated protein C mitigates thrombo-inflammatory CD4+ T cell activity present in Inflammatory Bowel Disease.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i216–i217, https://doi.org/10.1093/ecco-jcc/jjae190.0109
DOP071 Distinctive pathogenic memory T cell and neutrophil responses at diagnosis identify CD patients who develop severe therapy resistant disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i218, https://doi.org/10.1093/ecco-jcc/jjae190.0110
DOP072 The IL1-dependent transcription factor MEOX1 as a driver of differentiation programs in ACKR1+ endothelial cells of inflammatory bowel disease granulation tissue
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i219, https://doi.org/10.1093/ecco-jcc/jjae190.0111
DOP Session 9: Diagnostics and Fibrosis in IBD
DOP073 Gli1+ Mesenchymal Cells Drive Intestinal Fibrostenosis by Secreting SMOC2: A Biomarker and Therapeutic Target
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i220–i221, https://doi.org/10.1093/ecco-jcc/jjae190.0112
DOP074 JAK inhibition to target fibroblasts and IBD-related fibrosis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i222, https://doi.org/10.1093/ecco-jcc/jjae190.0113
DOP075 Tissue fibrosis modulates interleukin (IL)-13 signaling in intestinal epithelial cells
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i223–i224, https://doi.org/10.1093/ecco-jcc/jjae190.0114
DOP076 Translational and preclinical study validating anterior gradient 2 as a novel epithelial therapeutic target in Inflammatory Bowel Disease (IBD) involved in inflammation, fibrosis, and intestinal barrier integrity
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i225, https://doi.org/10.1093/ecco-jcc/jjae190.0115
DOP077 EndoUC: an AI-assisted endoscopic Ulcerative Colitis activity grading application for deployment in clinical trials
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i226–i228, https://doi.org/10.1093/ecco-jcc/jjae190.0116
DOP078 Machine learning assessment of endoscopic severity in Ulcerative Colitis trials: Model evaluation against the 2 + 1 reference standard
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i229–i230, https://doi.org/10.1093/ecco-jcc/jjae190.0117
DOP079 The impact of integrating pelvic MRI at diagnosis on early detection of perianal Crohn's disease in pediatrics
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i231, https://doi.org/10.1093/ecco-jcc/jjae190.0118
DOP080 Artificial Intelligence-Based Prediction of Nancy Grade Activity Using Digital Pathology in Ulcerative Colitis Patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i232–i233, https://doi.org/10.1093/ecco-jcc/jjae190.0119
DOP081 The EXTENT Study (Calculating the LEmann indeX using inTEstiNal ulTrasound): Results from an international expert Delphi consensus
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i234–i235, https://doi.org/10.1093/ecco-jcc/jjae190.0120
DOP Session 10: Clinical IBD
DOP082 Disease clearance prevents negative outcomes in ulcerative colitis patients and enhances the impact of independently achieving clinical, endoscopic, or histological remission.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i236–i237, https://doi.org/10.1093/ecco-jcc/jjae190.0121
DOP083 «Sonorescue»-treatment response in acute severe Ulcerative Colitis measured with ultrasound
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i238, https://doi.org/10.1093/ecco-jcc/jjae190.0122
DOP084 Development of a core outcome set for Inflammatory Bowel Disease patients with stomas
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i239, https://doi.org/10.1093/ecco-jcc/jjae190.0123
DOP085 Higher clinical remission and endoscopic response with vedolizumab in early versus late Crohn’s disease: data from the LOVE-CD trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i240–i241, https://doi.org/10.1093/ecco-jcc/jjae190.0124
DOP086 Burden of depression and anxiety among patients with pediatric-onset Inflammatory Bowel Diseases: A nationwide study from the epi-IIRN
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i242, https://doi.org/10.1093/ecco-jcc/jjae190.0125
DOP087 Characterization of a European population with recently diagnosed Crohn’s Disease: results from the prospective Crohn´s Disease Cohort (CROCO) Study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i243, https://doi.org/10.1093/ecco-jcc/jjae190.0126
DOP088 Speed of disease progression as hallmark of Crohn’s Disease Severity: The rapid and slow progressors.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i244–i246, https://doi.org/10.1093/ecco-jcc/jjae190.0127
DOP089 Shaping the Future of IBD Diagnostics: A Multicentric AI-Driven Capsule Endoscopy Study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i247, https://doi.org/10.1093/ecco-jcc/jjae190.0128
DOP090 Serum metabolites predict endoscopic disease activity and clinical and endoscopic remission in Ulcerative Colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i248–i250, https://doi.org/10.1093/ecco-jcc/jjae190.0129
DOP Session 11: Clinical Trials V
DOP091 Early serum infliximab levels predict outcomes in Acute Severe Ulcerative Colitis: results from PREDICT-UC
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i251, https://doi.org/10.1093/ecco-jcc/jjae190.0130
DOP092 Efficacy and safety of a second JAK inhibitor in Ulcerative Colitis : J2J multicenter cohort
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i252, https://doi.org/10.1093/ecco-jcc/jjae190.0131
DOP093 ECCO Topical Review on predictive models for IBD disease course and treatment response
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i253, https://doi.org/10.1093/ecco-jcc/jjae190.0132
DOP094 Improvement in biomarkers in patients with ulcerative colitis treated with vedolizumab: Results from the continuing VERDICT trial
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i254–i255, https://doi.org/10.1093/ecco-jcc/jjae190.0133
DOP095 IL-23-activated cells as response biomarkers for risankizumab in Crohn’s disease patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i256–i258, https://doi.org/10.1093/ecco-jcc/jjae190.0134
DOP096 Durability of TNF inhibitors in Crohn’s disease patients does not change with prior use of non-TNF agents
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i259–i261, https://doi.org/10.1093/ecco-jcc/jjae190.0135
DOP097 Emulsifier restriction is an effective therapy for active Crohn’s disease: the ADDapt trial - a multi-centre, randomised, double-blind, placebo-controlled, re-supplementation trial in 154 patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i262, https://doi.org/10.1093/ecco-jcc/jjae190.0136
DOP098 Development of BEN8744, a phase 2 ready, peripherally restricted PDE10 inhibitor targeting a new mechanism of action for the treatment of ulcerative colitis.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i263, https://doi.org/10.1093/ecco-jcc/jjae190.0137
DOP099 Prolonged Pharmacodynamic Effects of Risankizumab Following Withdrawal in Patients with Moderately to Severely Active Ulcerative Colitis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i264–i265, https://doi.org/10.1093/ecco-jcc/jjae190.0138
DOP Session 12: Clinical Trials and Diagnostics
DOP100 RXC008, a first-in-class gastrointestinal restricted pan-ROCK inhibitor developed for treatment of intestinal fibrosis shows GI restriction and tolerability: Results from the phase 1 program in healthy participants.
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i266, https://doi.org/10.1093/ecco-jcc/jjae190.0139
DOP101 Maintaining remission after an episode of steroid-responsive Acute Severe Ulcerative Colitis: what is the best strategy?
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i267–i269, https://doi.org/10.1093/ecco-jcc/jjae190.0140
DOP102 Comparative effectiveness of risankizumab vs. ustekinumab in bio-naïve Crohn's disease patients: A real-world multicentre retrospective cohort study
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i270–i271, https://doi.org/10.1093/ecco-jcc/jjae190.0141
DOP103 Optimization of Ustekinumab Treatment Induction Using a Pharmacokinetic Model in Inflammatory Bowel Disease Patients
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i272, https://doi.org/10.1093/ecco-jcc/jjae190.0142
DOP104 International differences in pre-operative characteristics and postoperative management in patients with Crohn’s disease following ileocolic resection: a report from the IMPACT consortium
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i273–i274, https://doi.org/10.1093/ecco-jcc/jjae190.0143
DOP105 Patient-reported quality of life in moderate-to-severe Crohn’s Disease and Ulcerative Colitis: Insights from the communicating needs and features of IBD experiences (CONFIDE) survey
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i275–i276, https://doi.org/10.1093/ecco-jcc/jjae190.0144
DOP106 Geographic disparities in Healthcare Utilisation in people with inflammatory bowel disease, Crohn’s Colitis Cure Data Insights Program
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i277–i278, https://doi.org/10.1093/ecco-jcc/jjae190.0145
DOP107 Real-time intestinal barrier assessment by endocytoscopy and confocal laser endomicroscopy uniquely correlates with multiple barrier protein expression and reflects the gut-brain axis
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i279–i280, https://doi.org/10.1093/ecco-jcc/jjae190.0146
DOP108 Inflammatory Bowel Disease and concomitant endometriosis: frequency and characteristics in a multidisciplinary approach
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Page i281, https://doi.org/10.1093/ecco-jcc/jjae190.0147
DOP Session 13: Basic Science in IBD
DOP109 A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i282–i283, https://doi.org/10.1093/ecco-jcc/jjae190.0148
DOP110 Optimized inflammatory and ER stress-induced phenotypes in differentiated intestinal organoids for modelling Inflammatory Bowel Disease
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i284–i286, https://doi.org/10.1093/ecco-jcc/jjae190.0149
